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The potential of induced pluripotent stem cells
(iPSCs) in disease modeling and regenerative medi-
cine is vast, but current methodologies remain ineffi-
cient. Understanding the cellular mechanisms under-
lying iPSC reprogramming, such as the metabolic
shift from oxidative to glycolytic energy production,
is key to improving its efficiency. We have developed
a lentiviral reporter system to assay longitudinal
changes in cell signaling and transcription factor ac-
tivity in living cells throughout iPSC reprogramming
of human dermal fibroblasts. We reveal early NF-kB,
AP-1, and NRF2 transcription factor activation prior
to a temporal peak in hypoxia inducible factor a
(HIFa) activity.Mechanistically, we show that an early
burst in oxidative phosphorylation and elevated reac-
tive oxygen species generation mediates increased
NRF2 activity, which in turn initiates the HIFa-medi-
ated glycolytic shift andmaymodulate glucose redis-
tribution to the pentose phosphate pathway. Criti-
cally, inhibition of NRF2 by KEAP1 overexpression
compromises metabolic reprogramming and results
in reduced efficiency of iPSC colony formation.
INTRODUCTION
The ability to genetically reprogram a somatic cell to an induced
pluripotent stem cell (iPSC) represented a paradigm shift in stem
cell research upon its first description (Takahashi and Yamanaka,
2006) and provides great promise for regenerative medicine, but
the process remains inefficient. It has been proposed that iPSC
reprogramming is a stochastic process (Hanna et al., 2009), but
there is emerging evidence that it is deterministic with initiation,Cestabilization, andmaturation stages (Golipour et al., 2012; Sama-
varchi-Tehrani et al., 2010) involving the coordinated temporal
activation and repression of cell signaling pathways (Park et al.,
2014; Polo et al., 2012). Reprogramming cells undergo profound
changes in morphology, function, and metabolic activity with so-
matic cells that predominantly rely onmitochondrial respiration to
produce ATP, switching to glycolysis (Folmes et al., 2011; Pano-
poulos et al., 2012; Prigione et al., 2010; Varum et al., 2011). The
opposite transition has also been shown to occur during differen-
tiation of human embryonic stem cells (hESCs; Cho et al., 2006)
and involves mitochondrial biogenesis. However, upon reprog-
ramming, human dermal fibroblast (hDF) mitochondria acquire
immature morphological features typical of those observed in
hESCs (Lonergan et al., 2006; Prigione et al., 2010), although their
relative density as a ratio to cytoplasmic volume remains broadly
the same (Zhang et al., 2011a).
Many stem cells, including hESCs, maintain quiescence and
potency in a physiologically hypoxic niche in vivo (Danet et al.,
2003; Ezashi et al., 2005; Morrison et al., 2000; Studer et al.,
2000). Furthermore, iPSC reprogramming (Shimada et al., 2012;
Yoshida et al., 2009) and the maintenance of hESC lines (Chen
et al., 2010) are enhanced under hypoxic conditions. Hypoxia
inducible factor-a (HIFa) transcription factor activity stimulates
glycolytic gene expression in adult stem cells (Paloma¨ki et al.,
2013) and cancer stemcells (Finley et al., 2011) andoccurs during
iPSC reprogramming (Prigione et al., 2014), with two recent
studies indicating that HIFa activation is integral to the upregula-
tionof glycolysis in the initiation stagesof iPSC reprogramming in-
dependent of oxygen tension (Prigione et al., 2014;Mathieu et al.,
2014). Specifically, Mathieu et al. (2014) show that ectopic
expression of the isoformHIF1a throughout iPSC reprogramming
promotes colony formation, whereas HIF2a overexpression en-
hances the early stages but is inhibitory in the later phases.
A major limitation in the study of transcription factor activity
driving metabolic reprogramming during iPSC generation, stem
cell differentiation, or tumor initiation is the ability to quantitatell Reports 14, 1883–1891, March 1, 2016 ª2016 The Authors 1883
activity in living cells. To date, only end-point or semiquantitative
fluorescent protein analyses have been employed in mechanistic
investigations of iPSC reprogramming (Hansson et al., 2012; Sa-
mavarchi-Tehrani et al., 2010). Herewe utilize a dual-reporter sys-
temwhere secreted NanoLuc luciferase (NLuc) and eGFP are ex-
pressed under the conditional control of a transcription factor
activated reporter (TFAR) and normalized for cell proliferation
against a second constitutively active secreted Vargula luciferase
(VLuc). Using this method, we are able to monitor transcription
factor activity in livecell cultures throughout iPSC reprogramming.
Froman initial screen of eight candidate transcription factors or
cell signaling pathways known to play a role in iPSC reprogram-
ming, we found a reproducible temporal wave of nuclear factor
kappa B (NF-kB), activator protein 1 (AP-1), and nuclear factor
(erythroid-derived 2)-like 2 (NRF2) activity prior to a distinct HIFa
peak, which correlatedwith themetabolic shift toward glycolysis.
NRF2,which isupregulatedwithin2daysof iPSCreprogramming,
is a master regulator of the stress response, particularly to
reactive oxygen species (ROS), and its activation is complex
andmultifactorial. Under conditions of homeostasis, NRF2 forms
proteasomal degradation complexes with two E3 ubiquitin ligase
adaptors: Kelch-like ECH-associated protein 1 (KEAP1) and
b-TrCP. Whereas p62/SQSTM1 competes with NRF2 for binding
to KEAP1, thus activating NRF2 signaling (Hayashi et al., 2015;
Ichimura et al., 2013), glycogen synthase kinase-3b (GSK-3b) in-
creases the binding of b-TrCP to NRF2, thus resulting in ubiquiti-
nation and proteasomal degradation of NRF2 (Chowdhry et al.,
2013). ROSexposurecausescysteinemodifications inKEAP1, al-
lowing newly translated NRF2 to evade ubiquitination and thus
mediate activation of genes containing antioxidant response ele-
ments in theirpromoters (Bairdetal., 2013;McMahonetal., 2006).
We show a longitudinal profile of NRF2 activity during iPSC re-
programming peaking at day 8 prior to initiation of a HIFa-medi-
ated glycolytic shift and thereafter decreasing to basal levels. In
contrast to the existing dogma, we show that in the early stages
of reprogramming, highly proliferative cells actually increase
mitochondrial respiration as well as channeling glucose to the
pentose phosphate pathway (PPP) to manage increased nucleo-
tide synthesis demands. The peaks in cell proliferation, oxidative
phosphorylation (OXPHOS), and PPP all correlate with maximal
NRF2 activity. Glycolysis increases in response to a transient
HIFa peak, which is in itself dependent on NRF2 activity. Our
data indicate that NRF2 activity is primarily affected through
increased ROS production in this context and can be reversed
by KEAP1 overexpression, which inhibits metabolic reprogram-
ming and results in drastically reduced iPSC colony formation.
We conclude that NRF2 acts at a critical nexus between coordi-
nating the distribution of glucose between catabolism and anab-
olismwhilemanaging the stress response and initiating themeta-
bolic switch during the initiation stages of iPSC reprogramming.
RESULTS
TFAR Lentiviral Transduction for Real-Time
Quantification of Transcription Factor Activity during
iPSC Reprogramming
In this study, we chose to use the latest iteration of the Yama-
naka iPSC reprogramming methodology employing episomally1884 Cell Reports 14, 1883–1891, March 1, 2016 ª2016 The Authorsmaintained plasmids (Yu et al., 2009). iPSCs generated using
this protocol were shown to exhibit pluripotent morphology
(Figure S1Ai), pluripotency-associated gene expression (Fig-
ure S1Aii), and protein expression (Figure 1A). iPSCs from this
protocol also formed embryoid bodies in vitro (Figures S1Bi–iii)
and teratomas in NOD/SCID mice (Figures S1Ci–iii) containing
tissues representative of all three germ layers.
We designed and produced seven TFAR lentiviral vectors
containing synthetic promoters activated by cell signaling
pathways previously implicated in iPSC reprogramming (Fig-
ure S1Di; sequences and validation can be found in Buckley
et al., 2015). For clarity, the ‘‘AP-1’’ synthetic promoter consists
of eight repeats of the sequence TGAGTCAG; thus, the TFAR
can be activated by either c-Fos/c-Jun heterodimers or
c-Jun/c-Jun homodimers (Park et al., 2003). We also included
a reporter vector with a truncated version of the ICAM1 pro-
moter because O’Malley et al. (2013) have previously reported
a critical temporal role for ICAM1 expression in the early stages
of mouse iPSC reprogramming. The lentiviral expression cas-
settes express secreted NLuc and are based on our previously
described vectors (Buckley et al., 2015). In order to control for
cell proliferation when using genome-integrating vectors, we
developed a second constitutively active lentiviral vector ex-
pressing the secreted VLuc (Figure S1Dii). NLuc and VLuc
have unique non-overlapping substrates whose activity is
independent of ATP. Specificity of our TFAR was confirmed
in transduced hDFs (<10 multiplicity of infection [MOI]) exposed
to relevant pathway agonists and antagonists (Table S1).
Expression of eGFP fluorescence and NLuc/VLuc luciferase
activity was assayed in conditioned medium over 72 hr (Figures
1Bi–iv and S2i–viii). All TFARs demonstrated modulation of
eGFP expression and significant changes in NLuc/VLuc ratio
within this timeframe.
TFAR activity was assayed throughout iPSC reprogramming
using the protocol shown in Figure 1C. NLuc/VLuc activity was
quantified in conditioned medium and expressed as a fold
change over NLuc/VLuc activity in control cultures transfected
with equivalent molar quantities of empty episomal plasmid.
Quality control was determined by the required emergence
of more than ten colonies per 1 3 105 cells after 25-days
post-transfection. FOXO and ICAM1 reporters showed no
significant changes in activity, but NFAT and NOTCH both
showed persistent repression during iPSC reprogramming
compared with controls from day 11 (Figures S3i–iv). Most
intriguingly, we observed early and significant increases in
NF-kB, AP-1, NRF2, and HIFa TFAR activity (Figure 1Di–v),
transcription factors previously associated with the stress/
antioxidant response (Gonchar and Mankovska, 2010).
Increased activity of these TFARs was validated by the
concomitant increased expression of established target genes
at day 2 (Figure S3v) and the observation of nuclear locali-
zation of c-Fos protein at day 4 in reprogramming cells
(Figure S3vi).
In this study, we focused on the peak in NRF2 activity at day 8
of iPSC reprogramming since NRF2 is the master regulator of
the antioxidant response. At this time point, NRF2 is localized
in both the cytoplasm and nucleus in reprogramming cells but
is largely excluded from the nucleus in control cells (Figure 2Ai).
Figure 1. Validation of Methodology
(A) Immunofluorescent cell staining for pluripotency marker expression.
(B) Validation of TFARs in hDFs.
(C) Schematic of the iPSC reprogramming protocol.
(D) Graphs to show fold change of normalized TFAR activity for iPSCs
compared with control cells, n = 9.
Scale bars represent 100 mm. MEF, mouse embryonic fibroblast; LTR,
long terminal repeat; PMA, phorbol myristate acetate. *p < 0.05, **p < 0.01,
***p < 0.005. Error bars represent SEM for three biological replicates. See also
Figures S1 and S3.
CeAn RNA-seq comparison of reprogramming and control cells at
day 8 also showed NRF2 target gene transcripts to be signifi-
cantly upregulated in reprogramming cells (Figure 2Aii). This
was also confirmed at the molecular level since the NRF2 target
genes thioredoxin 1 (TRX1), NAD(P)H dehydrogenase quinone 1
(NQO1), sulfiredoxin 1 (SRXN1), heme oxygenase 1 (HO-1), and
glutamate-cysteine ligase catalytic (GCLC) subunit were signifi-
cantly upregulated in reprogramming cells compared with con-
trol cells at day 8 (Figure 2Aiii). Consistent with our TFAR data
during iPSC reprogramming, HIF1a and its glycolytic target
GLUT1 were significantly upregulated at day 11 compared with
controls. Interestingly, HIF2a transcript expression was not
significantly altered in reprogramming cells compared with con-
trol cells at day 11 of reprogramming (Figure 2B). These data are
consistent with the observations of Mathieu et al. (2014).
We hypothesized that the early increase in NRF2 activity was
in response to elevated ROS generated from high levels of
mitochondrial activity in reprograming cells, so we analyzed
ROS levels using flow cytometry for 20,70-dichlorofluorescin di-
acetate (DCF-DA) at day 8 of iPSC reprogramming. Levels of
ROS were indeed higher in reprogramming cells compared
with control cells (Figure 2C). In addition to ROS, NRF2 can
be activated by the autophagy-associated p62 protein. There
was no quantifiable difference in p62 protein in lysates from
iPSC reprogramming cells either at day 2 or day 8 and no quan-
tifiable change in the autophagy-associated ATG5 protein at
day 2 (Figures 2D–2E). Additionally, we found no difference in
the levels of transcript expression of the NRF2 repressor pro-
tein KEAP1 at this time point (Figure S3vii), thus suggesting
that KEAP1 regulation is post-translational. This is consistent
with our hypothesis that modification of cysteine residues of
KEAP1 by ROS causes NRF2 activation at day 8 of iPSC
reprogramming.
Reprogramming Cells Temporarily Increase OXPHOS
and PPP Activity
If the observed elevated ROS levels were due to increased mito-
chondrial respiration during the early stages of iPSC reprogram-
ming, we would expect OXPHOS-mediated ATP production to
be increased. We used a luciferase assay to determine levels
of ATP produced when ATP synthase (Complex V), and therefore
ATP production by OXPHOS, was inhibited using oligomycin
A. We observed significantly higher levels of OXPHOS in re-
programming cells compared with control cells at day 8 of re-
programming (Figure 3A). This was also demonstrated by the
increased rates of routine and maximal oxygen consumption,
after injection of the uncoupling agent carbonyl cyanide 4-(tri-
fluoromethoxy) phenylhydrazone (FCCP), observed in pre-iPSCs
compared with controls at day 8 of iPSC reprogramming (Fig-
ure S3viii). This increase in mitochondrial OXPHOS activity and
capacity early in iPSC reprogramming correlated with a signifi-
cant increase in cell proliferation (Figure 3B) and is consistent
with associated increased metabolic demands.
Interestingly, this increase in OXPHOS at day 8 of iPSC re-
programming is supported by our RNA-seq data within which
there is a substantial enrichment of transcripts encoding
OXPHOS-related proteins at this time point (Figure 3C). Intrigu-
ingly, we also observed decreases in glycolysis by both analysisll Reports 14, 1883–1891, March 1, 2016 ª2016 The Authors 1885
Figure 2. Confirmation of TFAR Activation Data
(A) (i) Immunofluorescent cell staining to show NRF2 is localized in the nucleus of pre-iPSCs but largely excluded from the nucleus of control cells at day 8 of
reprogramming. (ii) Heatmap to show significantly altered NRF2 target gene expression in iPSCs and control cells at day 8 of reprogramming by RNA-seq. (iii)
qPCR to show upregulation of NRF2 target genes at day 8 of iPSC reprogramming compared to control cells.
(B) qPCR to show upregulation of HIF1a and its target GLUT1 at day 11 of iPSC reprogramming.
(C) Flow cytometry of DCF-DA to show increased ROS in pre-iPSCs at day 8 of reprogramming compared with control cells.
(D) Western blot analysis of p62 protein expression at day 8 of iPSC reprogramming.
(E) Western blot analysis of p62 and ATG5 transcript expression at day 2 of reprogramming.
n = 3 for all. Scale bars represent 100 mm. *p < 0.05, **p < 0.01. Error bars represent SEM for three biological replicates. ADAM22, A disintegrin and metal-
loprotease domain 22; BMP4, bone morphogenetic protein 4; c10orf105, chromosome 10 open reading frame 105; RNF114, ring finger protein 114; SEMA6A,
semaphorin-6A; TRIM9, tripartite motif containing 9; TTYH,: Tweety family member 1; CRIM1, cysteine-rich transmembrane BMP regulator 1; RPS6KA2,
ribosomal protein S6 kinase; TRX1, thioredoxin 1; NQO1, NAD(P)H dehydrogenase quinone 1; SRXN1, sulfiredoxin 1; HO-1, heme oxygenase 1; GCLC,
glutamate-cysteine ligase catalytic subunit. See also Figures S2 and S3.of ATP production when glycolysis is blocked by idoacetate
(IAA; Figure 3Di) and assessment of the rate of 3H2O production
from 3-3H-glucose (Figure 3Dii) after day 8 of iPSC reprogram-
ming. This would be consistent with glucose being shuttled
away from the glycolytic pathway and toward the PPP. PPP ac-
tivity was quantified by assessment of the difference between
14CO2 production from [1-
14C]-glucose (which decarboxylates
through the 6-phosphogluconate dehydrogenase-catalyzed
reaction) and that of [6-14C]-glucose (which decarboxylates
through the tricarboxylic acid cycle), as previously described
(Herrero-Mendez et al., 2009; Larrabee, 1990). PPP flux
increased concomitantly with the decrease in glycolytic flux
after day 8 in pre-iPSCs compared with control cells (Figure 3E).
Consistent with a programmed metabolic shift, increases
in glycolysis in iPSCs became significant at day 14, after the1886 Cell Reports 14, 1883–1891, March 1, 2016 ª2016 The AuthorsHIFa TFAR peak, and decreases in OXPHOS only become sig-
nificant by day 17 (Figures 3Fi and ii).
NRF2 Activates HIFa and Drives the Metabolic Switch
toward Glycolytic Energy Production
Our data indicated a significant role for ROS-induced NRF2 in
modulating the metabolic shift that occurs during iPSC reprog-
ramming, so we generated a KEAP1-overexpressing lentiviral
vector (KEAP1 O/E) to selectively inhibit NRF2 activity in trans-
duced cells. The ability of KEAP1O/E to decrease both NRF2 ac-
tivity (Figure 4Ai) and target gene expression (Figure 4Aii) was
confirmed in hDFs. We then subjected KEAP1 O/E and control
empty vector transduced (LNT CTL) cells to iPSC reprogram-
ming. KEAP1 O/E significantly inhibited HIFa TFAR activity at
day 11 of reprogramming (Figure 4Bi) and reduced transcript
Figure 3. Reprogramming Cells Experience Transient Increases in OXPHOS and PPP Flux and Decreases in Glycolysis
(A) ATP assay to show increased levels of ATP production by OXPHOS in iPSCs compared with control cells at day 8 of reprogramming.
(B) VLuc luciferase activity over time in pre-iPSCs and control cells.
(C) RNA-seq to show levels of expression of significantly altered OXPHOS-related genes in control cells versus iPSCs.
(D) (i) ATP assay to show decreased levels of ATP production by glycolysis at day 8 of reprogramming. (ii) Decreased glycolytic flux in iPSCs compared with
control cells.
(E) Increased PPP activity in reprogramming cells.
(F) ATP assays to show levels of OXPHOS (i) and (ii) glycolysis throughout reprogramming.
n = 3 for all. Error bars represent SEM for three biological replicates. *p < 0.05 **p < 0.005, ***p < 0.001. PRODH, proline dehydrogenase (oxidase) 1; PDHX,
pyruvate dehydrogenase complex component X; GRPEL1, GrpE-like 1; COX15, cytochrome c oxidase assembly homolog 15; COX5A, cytochrome c oxidase
subunit Va; CYCS, cytochrome c; AK4, adenylate kinase 4; MARS2, methionyl-tRNA synthetase 2; CLPB, ClpB caseinolytic peptidase B; PDSS1, prenyl (de-
caprenyl) diphosphatase synthase, subunit 1; ADCK3, aarF domain-containing kinase 3; FOXRED1, FAD-dependent oxidoreductase domain containing 1;
ACSS1, acyl CoA synthetase short-chain family member 1; CAT, catalase; BCL2L13, BCL2-like 13; SLC22A4, solute carrier family 22, member 4; COX7A1,
cytochrome c oxidase subunit VIIA, polypeptide 1 (muscle). See also Figure S3.levels of HIFa targets (Figure 4Bii). Furthermore, HIFa TFAR ac-
tivity was significantly enhanced by activation of NRF2 either
with deta NONOate, which induces mitochondrial ROS produc-
tion (Jacobson et al., 2005; Figures S4i–iii) or an NRF2-overex-
pressing adenovirus (NRF2 O/E; Figures S4iv–vi). KEAP1 O/E
also resulted in significantly lower levels of glycolysis, as as-
sessed by luciferase ATP assay after inhibition with IAA (Fig-
ure 4Ci) and lactate production by day 14 of reprogramming
(Figure 4Cii), whereas NRF2 activation either by deta NONOate
(Figure S4vii) or by NRF2 O/E (Figure S4viii) resulted in early in-
creases in the level of lactate production. Critically, KEAP1 O/E
also resulted in a 5-fold decrease in iPSC colony formation (Fig-
ure 4D). Taken together, these data indicate that NRF2 promotes
the metabolic shift from OXPHOS to glycolytic energy produc-
tion during iPSC reprogramming via HIFa activation.CeDISCUSSION
iPSC reprogramming is a fascinating biological phenomenon
that we still know very little about. It remains debatable whether
iPSC reprogramming is a stochastic series of events that
concludes in colony formation or occurs in a deterministic
stage-wise fashion. In this longitudinal study of transcription fac-
tor activity in hDF cell cultures during iPSC reprogramming, we
assessed the activity of seven transcription factors and ICAM1
gene regulation. ICAM1 was included due to the observations
of O’Malley et al. (2013) that mouse embryonic fibroblasts ob-
taining a CD44/ICAM1+ phenotype during iPSC reprograming
more efficiently transition to Nanog+ iPSC colonies. In contrast
to this group, we did not observe modulation of the ICAM1 pro-
moter during human iPSC reprogramming. This may be becausell Reports 14, 1883–1891, March 1, 2016 ª2016 The Authors 1887
Figure 4. NRF2 Promotes Metabolic Re-
programming of iPSCs via HIFa
(A) (i) Luciferase assay data to show decreased
levels of NRF2 activity in hDFs transduced with a
KEAP1 O/E lentivirus compared with a control
lentivirus (LNT CTL). (ii) qPCR to show decreased
expression of NRF2 targets in hDFs transduced
with a KEAP1 O/E lentivirus.
(B) (i) Luciferase assay data to show decreased
levels of HIFa TFAR activity in KEAP1 O/E cells
compared with LNT CTL cells at day 11 of iPSC
reprogramming. (ii) qPCR to showdecreased levels
of HIFa target gene expression in KEAP1 O/E cells
compared with LNT CTL cells at day 11 of iPSC
reprogramming.
(C) (i) ATP and (ii) lactate assays to show decreased
levels of glycolysis in KEAP1 O/E cells compared to
LNT CTL cells at day 14 of iPSC reprogramming.
(D) Alkaline phosphatase staining of iPSC colonies.
n = 3 for all. Error bars represent SEM for three
biological replicates. *p < 0.05, **p < 0.005, ***p <
0.001. O/E, overexpression. See also Figure S4.O’Malley et al. (2013) quantified cell surface protein rather than
transcriptional activation or may be due to species differences
between mouse and human cells. Interestingly, we also did not
detect any modulation of FOXO activity despite it being impli-
cated in establishing the pluripotent state in hESCs (Zhang
et al., 2011b). However, we did observe significant changes in
six TFARs; four increased and two decreased their activity during
iPSC reprogramming compared with controls. Levels of NFAT
and NOTCH activity were lower during iPSC reprogramming
compared with control sham reprogramming, which is consis-
tent with previous reports demonstrating that inhibition of these
pathways promotes pluripotency or self-renewal (Ichida et al.,
2014; Zhu et al., 2014). Most strikingly, we observed a repro-
ducible temporal wave of NF-kB, AP-1, NRF2, and HIFa activity.1888 Cell Reports 14, 1883–1891, March 1, 2016 ª2016 The AuthorsAll four TFARs were significantly upregu-
lated by day 2 with NF-kB and HIFa
dropping to control levels by day 4, while
AP-1 remained significantly elevated
compared with controls throughout.
NRF2 and HIFa activity peaked at days 8
and 11, respectively, prior to falling back
to control levels.
All four transcription factors with in-
creased activity during iPSC reprogram-
ming are associated with oxidative stress
responses (Reuter et al., 2010), so we
reasoned that their increased activity
was due to elevated ROS. As expected,
ROS levels were higher in iPSC reprog-
ramming compared with controls at day
8 when NRF2 activity was at its peak.
Our data corroborate previous findings
of high levels of ROS production in the
early stages of reprogramming in mouse
(Esteban et al., 2010) and human (Ji
et al., 2014) cells. Crucially, we showthat mitochondrial respiration is amplified during iPSC reprog-
ramming up to day 14. This is in agreement with, but extends
the observations of, Prigione et al. (2014), who showed that
mitochondrial respiration increased over the first 3 days of re-
programming. Numerous studies have shown that c-MYC can
induce ROS production (Esteban et al., 2010; Ji et al., 2014)
and conversely that ROS can cause differentiation of hESCs
(Ji et al., 2014). Furthermore, this has led to speculation that an-
tioxidants may increase the efficiency of iPSC reprogramming
by counteracting differentiation or preventing ROS-induced
damage (Mah et al., 2011). For example, antioxidant supple-
mentation with N-acetyl cysteine has been shown to promote
cell survival and prevent double-strand DNA breaks (Ji et al.,
2014), and supplementation with vitamin C has been shown to
promote histone demethylation (Esteban et al., 2010). Our data
showed that at the height of proliferative amplification reprog-
ramming cells had higher OXPHOS relative to control cells but
lower glycolysis. We rationalized that glucose was being redis-
tributed in reprogramming cells and found that indeed the PPP
was significantly increased in iPSC reprogramming compared
with controls at the height of NRF2 activity. Others have shown
that hESCs have an active PPP (Manganelli et al., 2012; Varum
et al., 2011) and that mature iPSCs have increased PPP activity
compared with their parental somatic cells (Varum et al., 2011).
However, we specifically map PPP activation to the initiation
stages of iPSC reprogramming and, crucially, demonstrate
that this activation occurs prior to the metabolic switch from
OXPHOS to glycolysis. Interestingly, and contradictory to its
role in some adult stem cells (Tsai et al., 2013), NRF2 has
been shown to increase the expression of components of the
PPP in cancer cells to facilitate increased proliferation (Mitsuishi
et al., 2012; Singh et al., 2013), suggesting that NRF2 may be
playing a similar role in this context. This would also provide
an additional mechanism by which NRF2 protects reprogram-
ming cells from oxidative stress since the reducing agent
NADPH is generated by PPP activity.
Our data imply that metabolic reprogramming occurs between
day 8 and day 14 of iPSC reprogramming in this system. This is
the period in which both NRF2 (day 8) and HIFa (day 11) activity
peaks. NRF2 peak activity preceded that of HIFa, so we sought
to investigate a functional link between the two transcription fac-
tors. Our data are consistent with ROS/KEAP1-mediated NRF2
activation, so we modulated NRF2 activity by genetic overex-
pression of KEAP1. Indeed, KEAP1 O/E resulted in a significant
reduction in expression of NRF2 target genes and, importantly, a
56% inhibition of the HIFa TFAR peak during iPSC reprogram-
ming compared with controls at day 11. In support of our hypoth-
esis, either NRF2 overexpression or ROS activation with deta
NONOate resulted in increased HIFa activation during reprog-
ramming. These data therefore place NRF2 upstream of HIFa
activation during iPSC reprogramming. Furthermore, KEAP1
O/E-mediated NRF2 inhibition resulted in reduced glycolytic
activation, whereas NRF2 activation resulted in increased glycol-
ysis. This demonstrates that NRF2-HIFa co-operation promotes
the metabolic switch to glycolytic energy production. Moreover,
KEAP1 O/E-mediated NRF2 inhibition reduced iPSC colony for-
mation consistent with the observations of Jang et al. (2014),
who showed that NRF2 shRNA transcript knockdown decreased
reprogramming efficiency. NRF2 has been shown to activate
HIF1a via TRX1 in lung adenocarcinoma A549 cells (Malec
et al., 2010). We speculate that the same mechanism may be
occurring during iPSC reprogramming, as we show here that
TRX1 is significantly increased during this process. Our demon-
stration of the central role of NRF2 in iPSC reprogramming is
consistent with the observation that cells with higher levels of
OXPHOS reprogram more readily (Esteban et al., 2010; Liu
et al., 2013), possibly due to increased NRF2 activity in these
cells.
In summary, we present evidence that the metabolic changes
occurring throughout iPSC reprogramming are more complex
than a simple switch from one predominant form of energy
production to another. Instead, they constitute a series of inter-Cemediate steps involving an initial increase in OXPHOS and
diversion of glucose from glycolysis to the PPP, before the
well-documented ‘‘metabolic switch’’ in which cells increase
glycolysis and decrease OXPHOS. We also demonstrate un-
equivocally that molecules controlling the cellular redox state
and metabolic states work together to facilitate the ultimate
transition from somatic to pluripotent cellular metabolism.
Elucidation of the molecular interactions between NF-kB,
AP-1, NRF2, and HIFa transcription factors and their potential
roles in the metabolic switch therefore warrants further investi-
gation since manipulation of the redox state using small mole-
cules has potential to improve iPSC reprogramming efficiency.
Finally, these data collectively add weight to the emerging
concept that, at least in the pre-colony forming initiation stages,
iPSC reprogramming is a stage-wise deterministic process with
quality-control checkpoints. This process shows intriguing
similarities with tumor initiation that warrants further investiga-
tion in order to guarantee the development of safe and effica-
cious regenerative medicine approaches.
EXPERIMENTAL PROCEDURES
iPSC Reprogramming of hDFs
hDFs were transduced with a MOI of <10 of the appropriate NLuc lenti-
viral vector or control pLNT-SFFV-VLuc vector 7 days prior to reprogram-
ming. Transduced hDFs were then dissociated using Trypsin/EDTA (Sigma)
and 5 3 105 cells transfected with either 2 mg of each episomal reprogram-
ming plasmid (pCXLE-hUL, pCXLE-hSK, pCXLE-hOCT3/4-shp53-F, and
pCXWB-EBNA1; Addgene) or 8 mg of the episomal control plasmid in electro-
poration buffer (Lonza) using an Amaxa Nucleofector according to the manu-
facturer’s instructions. After transfection, cells were seeded on a six-well
plate in complete DMEM (DMEM supplemented with 10% fetal bovine serum
[FBS], 1% non-essential amino acids [NEAAs], 4% 200 mM L-glutamine, and
1% penicillin/streptomycin [P/S]; all Sigma-Aldrich) without P/S, and medium
was changed every 2 days. At 8 days after transfection, 3 3 104 cells were
seeded per well in triplicate in a six-well plate containing mitotically inacti-
vated fibroblasts (MEFs) in iPSC media (DMEM/F12 containing Glutamax
supplementedwith 20% knockout serum replacement, 0.1 mM b-mercaptoe-
thanol [all Life Technologies] 1% P/S and 1% NEAA and 10 ng/ml FGF2 [R&D
Systems]). Medium was replenished every 2 days, and samples were taken
for luciferase assays as described. Each experiment was repeated at least
twice.
Appropriate hDFs were treated with 50 mM deta NONOate (ENZO life sci-
ences) on days 1–6 or NRF2 O/E adenovirus (a kind gift from Dr. Stephen
White) or the adenoviral control (AV CTL) on day 2.
Luciferase Assays
Supernatant was collected from triplicate wells of cells at the appropriate time
points, and 20 ml was transferred to 20 ml assay buffer (25 mM Tris Phosphate
[pH 7.8] containing 1% BSA and 30% glycerol; all Sigma-Aldrich) in a white-
bottomed 96-well plate (Corning) in technical triplicates. VLuc samples were
assayed detecting photonic emissions at 460 nm after addition of 5 nM vargu-
lin (Gold Biotechnology) and NLuc photonic emissions at 454 nm after addition
of 1 mM coelenterazine (Gold Biotechnology) using a Promega GloMax 96
luminometer.
Data Analysis
The following equation was used to analyze the data:
ðTFAR Nluc iPSC=SFFV Vluc iPSCÞ
ðTFAR Nluc control=SFFV Vluc controlÞ:
These values were then plotted graphically against the number of days post-
transfection.ll Reports 14, 1883–1891, March 1, 2016 ª2016 The Authors 1889
ATP Production Assays
Cells were plated on tissue culture-treated white-bottomed 96-well plates
(Corning) in triplicate per treatment. Cells were washed with complete
DMEM before appropriate compounds were added; 3 mM IAA (Sigma) was
used to block glycolysis, and 5 mM oligomycin A (Sigma) was used to block
OXPHOS. The plate was incubated at 37C for 1 hr before being analyzed us-
ing a Cell Titer Glo Luminescent Assay (Promega) according to the manufac-
turer’s instructions. The inverse of the mean value for levels of ATP produced
in the presence of the drugs divided by the total ATP produced was then
plotted graphically.
ROS Determination
Cells were washed with PBS and incubated in 5 mM DCF-DA in complete
DMEM for 30 min before being washed with PBS and dissociated with
Trypsin/EDTA. Cells were then resuspended in PBS and the levels of fluores-
cence in the FL1 channel analyzed using a FACSCalibur (BD Biosciences).
The excitation and emission wavelengths were set to 490 and 535 nm,
respectively.
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